MA45377A - Composés hétérocycliques en tant qu'agents antibacteriens - Google Patents
Composés hétérocycliques en tant qu'agents antibacteriensInfo
- Publication number
- MA45377A MA45377A MA045377A MA45377A MA45377A MA 45377 A MA45377 A MA 45377A MA 045377 A MA045377 A MA 045377A MA 45377 A MA45377 A MA 45377A MA 45377 A MA45377 A MA 45377A
- Authority
- MA
- Morocco
- Prior art keywords
- antibacterial agents
- heterocyclic compounds
- heterocyclic
- antibacterial
- compounds
- Prior art date
Links
- 239000003242 anti bacterial agent Substances 0.000 title 1
- 150000002391 heterocyclic compounds Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16174719 | 2016-06-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA45377A true MA45377A (fr) | 2019-04-24 |
Family
ID=56132837
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA045377A MA45377A (fr) | 2016-06-16 | 2017-06-15 | Composés hétérocycliques en tant qu'agents antibacteriens |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US11179396B2 (fr) |
| EP (1) | EP3472158A1 (fr) |
| JP (1) | JP2019518046A (fr) |
| KR (1) | KR20190017948A (fr) |
| CN (1) | CN109476657A (fr) |
| AU (1) | AU2017286368B2 (fr) |
| BR (1) | BR112018076126A2 (fr) |
| CA (1) | CA3026010A1 (fr) |
| EA (1) | EA201990043A1 (fr) |
| MA (1) | MA45377A (fr) |
| MX (1) | MX2018015656A (fr) |
| WO (1) | WO2017216281A1 (fr) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112017028318B1 (pt) | 2015-07-02 | 2024-02-20 | Janssen Sciences Ireland Uc | Composto antibacteriano, seu uso, processo para sua preparação,produto que o contém, composição farmacêutica e combinação |
| CN108348510B (zh) | 2015-09-17 | 2022-01-04 | 圣母大学 | 针对分枝杆菌感染有用的含有苄胺的杂环化合物以及组合物 |
| BR112018076126A2 (pt) | 2016-06-16 | 2019-03-26 | Janssen Sciences Ireland Unlimited Company | compostos heterocíclicos como antibacterianos |
| EP4417262A3 (fr) | 2017-03-01 | 2024-11-27 | Janssen Sciences Ireland Unlimited Company | Polythérapie |
| RU2764243C2 (ru) | 2017-09-22 | 2022-01-14 | ДЖУБИЛАНТ ЭПИПЭД ЭлЭлСи | Гетероциклические соединения в качестве ингибиторов PAD |
| AU2018352142B2 (en) | 2017-10-18 | 2022-08-25 | Jubilant Epipad LLC | Imidazo-pyridine compounds as PAD inhibitors |
| US11629135B2 (en) | 2017-11-06 | 2023-04-18 | Jubilant Prodell Llc | Pyrimidine derivatives as inhibitors of PD1/PD-L1 activation |
| PT3704120T (pt) | 2017-11-24 | 2024-07-03 | Jubilant Episcribe Llc | Compostos heterocíclicos como inibidores de prmt5 |
| MX2020009517A (es) | 2018-03-13 | 2021-01-20 | Jubilant Prodel LLC | Compuestos biciclicos como inhibidores de la interaccion/activacio n de pdl/pd-l1. |
| TWI861208B (zh) | 2019-09-10 | 2024-11-11 | 日商鹽野義製藥股份有限公司 | 對分枝桿菌感染有用之含苄胺的 5,6-雜芳族化合物 |
| WO2021048342A1 (fr) | 2019-09-13 | 2021-03-18 | Janssen Sciences Ireland Unlimited Company | Composés antibactériens |
| US20220396586A1 (en) * | 2019-09-26 | 2022-12-15 | The Global Alliance For Tb Drug Development, Inc. | Thiazole carboxamide compounds and use thereof for the treatment of mycobacterial infections |
| JP2022551823A (ja) | 2019-09-30 | 2022-12-14 | ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー | 抗菌化合物 |
| AU2020358643A1 (en) | 2019-09-30 | 2022-05-26 | Janssen Sciences Ireland Unlimited Company | 4-quinolinone antibacterial compounds |
| EP4308239A1 (fr) | 2021-03-16 | 2024-01-24 | Janssen Sciences Ireland Unlimited Company | Composés antibactériens |
| CN117440958A (zh) * | 2021-03-17 | 2024-01-23 | 爱尔兰詹森科学公司 | 抗菌化合物 |
| MX2023010948A (es) | 2021-03-17 | 2023-11-28 | Janssen Sciences Ireland Unlimited Co | Compuestos antibacterianos. |
| WO2022214519A1 (fr) | 2021-04-07 | 2022-10-13 | Janssen Sciences Ireland Unlimited Company | Composés antibactériens |
| WO2022214520A1 (fr) | 2021-04-07 | 2022-10-13 | Janssen Sciences Ireland Unlimited Company | Composés antibactériens |
| IL312366A (en) | 2021-10-28 | 2024-06-01 | Janssen Sciences Ireland Unlimited Co | Imidazopyridine amides and related compounds for use in the treatment of bacterial infections |
| WO2024089170A1 (fr) | 2022-10-27 | 2024-05-02 | Janssen Sciences Ireland Unlimited Company | Composés antibactériens |
| WO2024223859A1 (fr) | 2023-04-26 | 2024-10-31 | Janssen Pharmaceutica Nv | Composés antibactériens |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT792273E (pt) | 1994-11-15 | 2003-06-30 | Upjohn Co | Produtos antibacterianos de oxazolidinona substituida com oxazina e tiazina biciclicas |
| DE69614847T2 (de) * | 1995-05-11 | 2002-04-04 | Pharmacia & Upjohn Co., Kalamazoo | Spirocyclische und bicyclische diazinyl- und carbazinyloxazolidinone |
| DK1527050T3 (da) | 2002-07-25 | 2010-07-19 | Janssen Pharmaceutica Nv | Quinolin-derivater og deres anvendelse som mycobakterielle inhibitorer |
| AR042956A1 (es) | 2003-01-31 | 2005-07-13 | Vertex Pharma | Inhibidores de girasa y usos de los mismos |
| MA27360A1 (fr) | 2004-11-23 | 2005-06-01 | Brahim Bennani | Synthese et application des spiro-isoxazolines comme agents anti-tuberculeux |
| CN101631786A (zh) | 2006-12-20 | 2010-01-20 | 先灵公司 | 新颖的jnk抑制剂 |
| TW200901969A (en) | 2007-06-06 | 2009-01-16 | Smithkline Beecham Corp | Chemical compounds |
| TWI498115B (zh) | 2007-12-27 | 2015-09-01 | Daiichi Sankyo Co Ltd | 咪唑羰基化合物 |
| JP5613656B2 (ja) | 2008-03-26 | 2014-10-29 | グローバル、アライアンス、フォア、ティービー、ドラッグ、ディベロップメント | 置換されたフェニルオキサゾリジノンと共有結合した二環式ニトロイミダゾール |
| JP2012503206A (ja) | 2008-09-22 | 2012-02-02 | オレゴン ヘルス アンド サイエンス ユニバーシティ | Mycobacteriumtuberculosis感染を検出するための方法 |
| JP2012514044A (ja) | 2008-12-30 | 2012-06-21 | ミレニアム ファーマシューティカルズ, インコーポレイテッド | Rafキナーゼ阻害剤として有用なヘテロアリール化合物 |
| EP2496578A4 (fr) | 2009-11-05 | 2013-08-21 | Univ Notre Dame Du Lac | Composés d'imidazo[1,2-a]pyridine, leur synthèse et procédés pour les utiliser |
| CA2793086C (fr) * | 2010-03-18 | 2018-08-21 | Institut Pasteur Korea | Composes d'imidazo[1,2-a]pyridine substitue et leur utilisation pour le traitement d'infections bacteriennes |
| KR102104125B1 (ko) | 2011-04-21 | 2020-05-29 | 재단법인 한국파스퇴르연구소 | 소염 화합물 |
| US9199981B2 (en) | 2011-09-01 | 2015-12-01 | Novartis Ag | Compounds and compositions as C-kit kinase inhibitors |
| EP2751104B1 (fr) | 2011-09-01 | 2019-09-25 | Novartis AG | Composés et compositions en tant qu'inhibiteurs de kinase c-kit |
| US9822129B2 (en) | 2012-03-02 | 2017-11-21 | Genentech, Inc. | Amido spirocyclic amide and sulfonamide derivatives |
| KR101918469B1 (ko) | 2012-06-04 | 2018-11-15 | 한국화학연구원 | 바이사이클릭 니트로이미다졸 유도체 또는 이들의 광학이성질체, 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 약제학적 조성물 |
| US9605002B2 (en) * | 2012-07-18 | 2017-03-28 | University Of Notre Dame Du Lac | 5,5-heteroaromatic anti-infective compounds |
| JP6250667B2 (ja) * | 2012-08-10 | 2017-12-20 | ヤンセン・サイエンシズ・アイルランド・ユーシー | 新しい抗菌化合物 |
| KR101650716B1 (ko) | 2012-11-22 | 2016-08-24 | 한국화학연구원 | 바이시클릭니트로이미다졸 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 결핵의 예방 또는 치료용 약학적 조성물 |
| DK3027615T3 (da) * | 2013-08-02 | 2021-10-25 | Pasteur Institut Korea | Antiinfektionsforbindelser |
| KR101564425B1 (ko) | 2013-11-26 | 2015-10-30 | 한국화학연구원 | 신규한 바이사이클릭 니트로이미다졸 카바메이트 화합물, 이를 제조하는 방법 및 이를 유효성분으로 함유하는 결핵 질환의 예방 또는 치료용 약제학적 조성물 |
| CN105524058B (zh) | 2014-10-21 | 2018-03-27 | 广州艾格生物科技有限公司 | 吡唑并[1,5‑a]吡啶类化合物及其应用 |
| WO2016073524A1 (fr) | 2014-11-03 | 2016-05-12 | The Regents Of The University Of California | Multithérapies médicamenteuses pour le traitement de la tuberculose |
| BR112017028318B1 (pt) | 2015-07-02 | 2024-02-20 | Janssen Sciences Ireland Uc | Composto antibacteriano, seu uso, processo para sua preparação,produto que o contém, composição farmacêutica e combinação |
| MX2018015657A (es) | 2016-06-16 | 2019-03-14 | Janssen Sciences Ireland Unlimited Co | Compuestos heterociclico como antibacterianos. |
| BR112018076126A2 (pt) | 2016-06-16 | 2019-03-26 | Janssen Sciences Ireland Unlimited Company | compostos heterocíclicos como antibacterianos |
| EP4417262A3 (fr) | 2017-03-01 | 2024-11-27 | Janssen Sciences Ireland Unlimited Company | Polythérapie |
-
2017
- 2017-06-15 BR BR112018076126-5A patent/BR112018076126A2/pt not_active Application Discontinuation
- 2017-06-15 US US16/309,725 patent/US11179396B2/en not_active Expired - Fee Related
- 2017-06-15 CA CA3026010A patent/CA3026010A1/fr not_active Abandoned
- 2017-06-15 WO PCT/EP2017/064652 patent/WO2017216281A1/fr not_active Ceased
- 2017-06-15 AU AU2017286368A patent/AU2017286368B2/en not_active Ceased
- 2017-06-15 KR KR1020197000960A patent/KR20190017948A/ko not_active Ceased
- 2017-06-15 JP JP2018565675A patent/JP2019518046A/ja active Pending
- 2017-06-15 CN CN201780037229.4A patent/CN109476657A/zh active Pending
- 2017-06-15 EA EA201990043A patent/EA201990043A1/ru unknown
- 2017-06-15 EP EP17729877.5A patent/EP3472158A1/fr not_active Withdrawn
- 2017-06-15 MA MA045377A patent/MA45377A/fr unknown
- 2017-06-15 MX MX2018015656A patent/MX2018015656A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EA201990043A1 (ru) | 2019-05-31 |
| MX2018015656A (es) | 2019-03-14 |
| JP2019518046A (ja) | 2019-06-27 |
| CA3026010A1 (fr) | 2017-12-21 |
| KR20190017948A (ko) | 2019-02-20 |
| AU2017286368B2 (en) | 2021-02-25 |
| AU2017286368A1 (en) | 2018-12-06 |
| WO2017216281A1 (fr) | 2017-12-21 |
| US20190134046A1 (en) | 2019-05-09 |
| EP3472158A1 (fr) | 2019-04-24 |
| BR112018076126A2 (pt) | 2019-03-26 |
| US11179396B2 (en) | 2021-11-23 |
| CN109476657A (zh) | 2019-03-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA45377A (fr) | Composés hétérocycliques en tant qu'agents antibacteriens | |
| MA45375A (fr) | Composés hétérocycliques utilisés en tant qu'agents antibacteriens | |
| MA55194A (fr) | Composés hétérocycliques en tant qu'immunomodulateurs | |
| MA43169A (fr) | Composés hétérocycliques utilisés en tant qu'inhibiteurs de pi3k-gamma | |
| MA51878A (fr) | Composés d'aminothiazole en tant qu'inhibiteurs de c-kit | |
| MA53150A (fr) | Composés de benzimidazole en tant qu'inhibiteurs de c-kit | |
| MA42990A (fr) | Composés utiles en tant qu'immunomodulateurs | |
| MA51438A (fr) | Composés hétérocycliques utilisés en tant qu'inhibiteurs de lsd1 | |
| EP3533787A4 (fr) | Composé de pyridone en tant qu'inhibiteur de c-met | |
| MA47099A (fr) | Composés hétéroaromatiques bicycliques utilisés en tant qu'immunomodulateurs | |
| EP3386981A4 (fr) | Hétérocycles utiles en tant qu'agents anticancereux | |
| MA47013A (fr) | Composés benzolactames utilisés en tant qu'inhibiteurs de protéine kinase | |
| MA47123A (fr) | Dérivés de benzooxazole en tant qu'mmunomodulateurs | |
| MA46091A (fr) | Composés biaryles utiles en tant qu'immunomodulateurs | |
| MA40587A (fr) | Composés d'aminopyrimidinyle en tant qu'inhibiteurs de jak | |
| EP3621624A4 (fr) | Composés dinucléotidiques cycliques en tant qu'agonistes sting | |
| MA52063A (fr) | Composés de n-((hét)arylméthyl)hétéroaryle-carboxamides en tant qu'inhibiteurs de la kallicréine plasmatique | |
| MA47120A (fr) | Dérivés pyridine utilisés en tant qu'immunomodulateurs | |
| MA49374A (fr) | Composés hétéroaromatiques utilisés en tant qu'inhibiteurs de vanine | |
| EP3883570A4 (fr) | Hétérocycles fonctionnalisés utiles en tant qu'agents antiviraux | |
| EP3464275A4 (fr) | Composés inhibiteurs de l'egfr | |
| MA54567A (fr) | Pyridine et composés de pyridimine en tant qu'inhibiteurs de pi3k-gamma | |
| MA41551A (fr) | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 | |
| MA46878A (fr) | Composés de benzodiazolium en tant qu'inhibiteurs d'enac | |
| EP2989106A4 (fr) | Composés hétérocycliques fusionnés en tant qu'inhibiteurs de protéine kinase |